Overview

Clinical Study of Universal CD19 CAR-T Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This study is an open-label, single-arm clinical trial designed to evaluate the safety and tolerability of QH103 cell injection solution in adult subjects with relapsed/refractory CD19-positive B-cell lymphoma.

Phase:

PHASE1

Details

Lead Sponsor:

The Second Affiliated Hospital of Fujian Medical University

Treatments:

Cyclophosphamide
fludarabine